CCO_Clin_Onc_June_2013_Myeloma课件.pptVIP

下载本文档

3
0
约3.87万字
约 54页
2017-02-19 发布于河南
举报
版权申诉

CCO_Clin_Onc_June_2013_Myeloma课件.ppt

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

ECOG, Eastern Cooperative Oncology Group; IMWG, International Melanoma Working Group; IV, intravenous; MM, multiple myeloma; PS, performance score. * IMWG, International Melanoma Working Group; MR, molecular response; PFS, progression-free survival; PR, partial response. * AST, aspartate aminotransferase; DLT, dose-limiting toxicity. * CR, clinical response; MR, molecular response; PFS, progression-free survival; PR, partial response. * DLT, dose-limiting toxicity; IMiD, immunomodulatory drug; MTD, maximum tolerated dose; ORR, overall response rate; PD, progressive disease. * MR, molecular response; MTD, maximum tolerated dose; ORR, overall response rate; PR, partial response; SD, stable disease; VGPR, very good partial response. * AE, adverse event; MTD, maximum tolerated dose; SAE, serious adverse event. * DLT, dose-limiting toxicity; MTD, maximum tolerated dose. * GI, gastrointestinal; MTD, maximum tolerated dose. * * CR, complete response; MRD, minimal residual disease; VGPR, very good partial response. * MRD, minimal residual disease. * MCR, molecular complete response; MRD, minimal residual disease; OS, overall survival; PFS, progression free survival. * ICR, immunophenotypic complete response; MRD, minimal residual disease; OS, overall survival; PFS, progression free survival. * CR, complete response; MRD, minimal residual disease. * * MEL200, melphalan 200 mg/m2; MPR, melphalan/prednisone/lenalidomide; NDMM, newly diagnosed multiple myeloma; PFS, progression-free survival, PD, progressive disease. * MEL200, melphalan 200 mg/m2; MPR, melphalan/prednisone/lenalidomide; OS, overall survival, PFS, progression-free survival. * Len, lenalidomide; MEL200, melphalan 200 mg/m2; MPR, melphalan/prednisone/lenalidomide; OS, overall survival; PFS, progression-free survival. * CR, complete response; MEL200, melphalan 200 mg/m2; MPR, melphalan/prednisone/lenalidomide; OS, overall survival; PFS, progression-free survival; PR, partial response; VGPR, very good partial re